Eris Lifesciences Q1 Review – Strength Of Core Portfolio Beats Estimates, IPM: Prabhudas Lilladher

BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Prabhudas Lilladher Report

Eris Lifesciences Ltd.’s strong growth outlook wih high contibution of chronic/sub-chronic products, pure domestic play with insignificant regulatory risks, steady return on equity of 35% plus and resilience of margins drives our upgrade in valuation multiples.

With strong pipeline of patent expiration opportunities in cardio-metabolic segment, we maintain our positive outlook of 14%/ 16%/ 18% compound annual growth rate in FY21-23E with average Ebitda margin of 35%.

Eris Lifesciences guided 15% sales growth with Ebitda margin of around 35-36% in FY22E.

It is confident to maintain the trend considering launch of more than 10 products every year plus major launches expected in Q4 FY22E and Q1 FY23E.

Click on the attachment to read the full report:

Prabhudas Lilladher Eris Lifesciences Q1FY22 Result Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Most Related Links :
thereliablenews Governmental News Finance News

Source link

Back to top button